Kornimate/medical-research-clean huggingface dataset:
finger robot therapy study

Conditions: Cerebrovascular Accident

Summary: the purpose of this study is to determine the effectiveness of training hand movement using finger robot after stroke. finger is a robot that measures finger movements and allows users to play computer games using those movements.

robotic devices can be used to retrain movement after stroke. however, it is unclear how best to assist in movement. providing physical assistance may improve the flow of proprioceptive information to the nervous system, which may help a person relearn to move a limb. on the other hand, assisting movement with a robot may cause a person to "slack", not trying as hard during therapy. this study will test the effect of different levels of assistance on recovery of finger function during robot-assisted therapy after stroke.

Eligibility criteria:
inclusion criteria: * age 18 to 80 years of age * have history of stroke affecting the arm, at least 6 months prior to enrollment * have arm and/or hand weakness as measured on a standard clinical scale * do not have active major psychological problems, or problems affecting the stroke-affected arm or hand besides the stroke * do not have active major brain disease other than the stroke * have absence of pain in the stroke-affected arm and hand exclusion criteria: * severe stiffness of the arm or hand as measured on a standard clinical scale * severe problems speaking or understanding speech as measured on a standard clinical scale * severe reduced level of consciousness * severe loss ability to sense movement of your limbs as measured on a standard clinical scale * currently pregnant * difficulty in understanding or complying with the instructions given by the researcher * inability to perform the experimental task that will be studied * increased pain with movement of the stroke-affected arm or hand exclusion criteria that will prevent subjects from participating in the mri: * subjects having any implanted metal such as metallic splinters, metallic surgical clips, prosthetic heart valves, pacemakers, neuro-stimulation devices, orthodontic work that contains ferromagnetic materials, * subjects whose occupation or activities may cause accidental lodging of ferromagnetic materials, or that may have imbedded metal fragments from military activities, unless cleared by a screening head ct scan * subjects with tattoo(s) presenting metallic or ferromagnetic color ingredients or with facial make-up * subjects who have claustrophobia * subjects who are currently pregnant or breastfeeding.

Keywords: stroke
copeptin testing during pre-hospital care in the treatment of chest pain suggestive of acute coronary syndrome

Conditions: Chest Pain

Summary: the main objective of our study is to evaluate the diagnostic value of copeptin testing in association with troponin hs testing during pre-hospital care (ambulance care) in the treatment of patients whose pattern of use is the occurrence chest pain suggestive of acs but not st+.

the secondary objectives of this study are to: a. evaluate the diagnostic value of determination of copeptin testing in pre-hospital care in another diagnosis; b. assess the prognostic value of copeptin assay on vital prognosis at day 28; c. evaluate the kinetics of copeptin and troponin hs between initial ambulance care and arrival at the emergency department; d. evaluate the potential impact of copeptin testing on pre-hospital patient care; e. assess the economic impact of pre-hospital copeptin testing in terms of hospital stays and optimizing ambulance movements.

Eligibility criteria:
inclusion criteria: * all major adult patients taken in charge by the emergency ambulance services of the participating centers for non-traumatic chest pain for suspected acs and an electrocardiogram initially excluding an st segment elevation exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient (or a legal representative) formalizes his/her opposition for the study * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * the patient has a contraindication for a treatment used in this study * the patient's initial electrocardiogram indicates an st segment elevation

Keywords: copeptin troponin hs
skeletal muscle wasting in icu patients

Conditions: Critical Illness; Muscle Atrophy

Summary: muscle wasting occurs rapidly in critically ill patients and impacts both short and long term outcomes. altered protein metabolism drives muscle loss in icu patients, with muscle protein breakdown exceeding muscle protein synthesis (mps). interventions aimed at attenuating muscle loss by stimulating mps rates are hampered by a lack of knowledge on altered muscle protein turnover rates during critical illness. only a few studies have specifically assessed muscle protein synthesis by using contemporary intravenous stable isotope infusions, which allows the assessment of mps over a short (\<9 hours) period of time. results from such acute studies can be difficult to extend or translate into long-term clinical practice and outcomes. oral deuterated water (2h2o) dosing provides an alternative method that can be utilized to extend the measurement of muscle protein synthesis over a period of several days or weeks. it could therefore provide a valuable tool to study muscle protein synthesis during icu admission and the impact of different anabolic interventions. although multiple studies using the deuterated water methodology have been performed in both healthy volunteers and patients, it has not yet been performed in critically ill patients. in this prospective study the investigators aim to assess fractional rates of muscle protein synthesis over a period of (maximal) 7 days in critically ill patients admitted to the intensive care unit. secondly, the investigators aim to assess mechanisms of acute muscle wasting on an microscopic, ultrastructural and molecular level. furthermore, the investigators aim to investigate to what extent muscle fibre size is recovered 3 months after icu discharge.


Eligibility criteria:
inclusion criteria: * age \>18y * admitted to icu * enteral nutrition line in situ * arterial line (any location) in situ * expected stay icu \>7d exclusion criteria: * spinal cord injury * chronic use of corticosteroids before hospital admission * contraindication to enteral infusion (e.g. due to gi-tract perforation) * kidney or liver failure * therapeutic anti coagulation
evolutionary systems therapy for schizotypy

Conditions: Schizotypal Personality Disorder

Summary: this study aims at replicating existing preliminary evidence about the effectiveness of evolutionary systems therapy for schizotypy (ests). the present randomized controlled trial (rct) will compare ests with cognitive behavioral therapy (cbt) in treating schizotypal personality disorder (spd). the main questions our rct aims to answer are: 1. is ests more effective than cbt in treating spd? 2. is ests more feasible than cbt in treating spd? 38 patients diagnosed with spd will be recruited and randomly allocated to either the experimental group (i.e. ests) or the control group (cbt). primary outcome will be reduction in general symptomatology, whereas secondary outcomes will be changes in target mechanisms (self-criticism and metacognition) and remission from diagnosis.

a previous study suggested how ests (experimental group; eg) may be not inferior in respect to a combine treatment comprising of cbt and psychopharmacological treatment (control group; cg). despite the encouraging results, it has been suggested that the presence in the cg of a mandatory pharmacological treatment would have represented a bias. indeed, a few partecipants refused pharmacological treatment. thus, the investigators outlined an rct aimed at comparing the two interventions (ests and cbt) without any mandatory pharmacological treatment. moreover, the investigators consider the need for a pharmacological treatment during the study as an exclusion criterion. the investigators expect to extend our knowledge about the feasbility and effectiveness of ests for those diagnosed with spd:

Eligibility criteria:
inclusion criteria: * diagnosis of schizotypal personality disorder at scid-5-ampd module iii * age 18 or older * being capable of reading and signing the inform consent form in italian * being capable of attending a talk therapy in italian exclusion criteria: * being diagnosed with schizophrenia spectrum disorders or other psychosis disorder * being diagnosed with neurodevelopmental or neurological disorders * being diagnosed with bipolar disorder * being under any psychological or pharmacological treatment

Keywords: compassion metacognition personality disorder schizotypy
studying tissue samples from women who underwent chemotherapy for lymph node-positive stage ii or stage iiia breast cancer on clinical trial clb-9741 or clb-9344

Conditions: Breast Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors plan the best treatment. purpose: this research study is looking at tissue samples from women who underwent chemotherapy for lymph node-positive stage ii or stage iiia breast cancer.

objectives: primary * to identify biomarkers that can be used to individually tailor the use of adjuvant dose-dense therapy in women with stage ii or iiia breast cancer. secondary * to identify groups of patients who have a poor prognosis despite adjuvant chemotherapy and who should be prospectively targeted for new approaches to adjuvant treatment. outline: this is a multicenter study. tissue samples are collected from patients. tissue samples are analyzed by immunohistochemistry (ki67, ck5/6, egfr, er) and fluorescence in situ hybridization (fish).

Eligibility criteria:
disease characteristics: * diagnosis of node-positive breast cancer * stage ii-iiia disease * underwent adjuvant chemotherapy on trial clb-9741 or clb-9344 * hormone receptor status not specified

Keywords: stage ii breast cancer stage iiia breast cancer
natural history study of usher syndrome ( light4deaf )

Conditions: Usher Syndromes

Summary: clinical centres in the light4deaf consortium have developed and will continue to improve a reliable, early molecular diagnosis and protocols for full clinical characterisation of usher syndrome, which will be valuable for the foreseen ush clinical trials. the clinical arm of the project aims at performing a deep-phenotyping of retinal degeneration, hearing loss, vestibular dysfunction, neurocognitive ability of subects with a molecular diagnosis of any usher syndrome. functional and structural parameters for retinal, auditory, and vestibular impairments are followed overtime to document the natural history of the disease and establish relevant clinical endpoint for disease progression that may be useful for future clinical trials.

our cohort study aims at precisely documenting ophthalmic, auditory, vestibular, cogninitive alterations over time with phenotype/genotype correlation ophthalmological assessment; best corrected visual acuity, kynetic perimetry, microperimetry, colour contrast sensitivity, retinal multimodal imaging (fundus photograph, fundus autofluorescence, sd-oct, octa, adaptive optics) ent assessment: tone and voice audiometry, distortion product otoacoustic emissions language assessment for children vestibular assessment: complete assessment of vestibular, canal and otolithic function neuro-cognitive and visio spatial assessment genetic: deep-genotyping using next generation sequencing

Eligibility criteria:
inclusion criteria: * patient with a molecular diagnosis of usher syndrome type i, ii or iii or a clinical diagnosis of usher syndrome type i, ii or iii which will then be confirmed by a molecular diagnosis * health insurance beneficiary * informed consent signed by the patient or their legal representatives exclusion criteria: • patient or his/her legal representatives unable to understand the study and for whom informed consent cannot be obtained

Keywords: usher syndrome, natural history study for retinal degenetation, deep-phenotyping, hearing loss, vestibular dysfunction
protein turnover in preterm infants - feeding of target fortified breast milk with different macronutrient composition to improve growth

Conditions: Infant Development; Protein-energy; Imbalance; Protein Deposition

Summary: the purpose of this study is to measure protein turnover rates in preterm infants.

after being informed about the study and potential risks, all parents giving written informed consent the principal investigator will determine the eligibility for study entry. patients who met the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to fortified breast milk with higher fat composition to fortified breast milk with higher carbohydrate composition. both groups will receive a stable protein composition. the participants will receive the intervention for 3 consecutive weeks.

Eligibility criteria:
inclusion criteria: * gestational age \< 32 weeks * enteral nutrition \>150 ml / kg / d exclusion criteria: * gastrointestinal malformations * enterostoma * short bowel syndrome * necrotizing enterocolitis * kidney disease * foreseeable transfer

Keywords: protein turnover growth tracer macronutrients
timing of periodontal re-evaluation after non-surgical periodontal therapy

Conditions: Periodontitis

Summary: literature on non surgical periodontal therapy (nspt) shows lack of clarity in reporting information on re-evaluation timing and clinical response. if the re-evaluation was done shortly after nspt, this is also likely to have an influence on the surgical treatment plan. the aim of this prospective clinical trial is to investigate the effect of re-evaluation timing at 1-3-6 months after nspt in terms of pocket closure, pd reduction, comprehensive treatment plan, and costs for the patient.


Eligibility criteria:
inclusion criteria: * periodontitis stage iii-iv * full-mouth plaque score (fmps) \< 25% at the 1-month re-evaluation * full-mouth bleeding score (fmbs) \< 25% at the 1-month re-evaluation * signed informed consent exclusion criteria * age \< 18 yo * pregnancy or lactation * heavy smokers (\>10 die) * conditions or diseases influencing periodontal healing * patients that cannot complete the 6 months follow-up
the effect of roux-en-y gastric bypass on insulin sensitivity in type 2 diabetes

Conditions: Type 2 Diabetes; Obesity

Summary: gastric bypass surgery induces remission of diabetes within days after surgery, before significant weight loss. the aim of the study is to examine whether improved insulin sensitivity of muscle and liver contributes to the immediate diabetes resolution.

obesity has become a severe epidemic globally. with the rapid increase in obesity comes a pronounced rise in obesity-related disorders, especially type 2 diabetes. weight loss achieved through lifestyle changes improves diabetes, but is very difficult to maintain over time. in contrast, roux-en-y gastric bypass (rygb) surgery can induce long-term weight loss and remission of diabetes. surprisingly, the resolution of type 2 diabetes occurs within days after surgery and before significant weight loss. the resolution of diabetes must therefore be explained by a response to the surgical alterations of the stomach and intestines: restriction in gastric volume and bypass of the stomach, duodenum and proximal jejunum. severe insulin resistance in muscle and liver is the common defect in obesity and type 2 diabetes and may be improved or even reversed shortly after the operation. the aim of this study is to examine the acute changes in insulin sensitivity of muscle and liver by using hyperinsulinaemic euglycaemic clamp combined with glucose tracer to assess hepatic glucose production. insulin signaling pathways will be studied in biopsies from muscle and subcutaneous fat as to explain the molecular basis of the changes in insulin sensitivity after rygb. insulin secretion will be evaluated in response to oral glucose as well as iv glucose-glucagon.

Eligibility criteria:
inclusion criteria: * patients eligible for gastric bypass surgery * verified type 2 diabetes or normal glucose tolerance by oral glucose tolerance test (ogtt) exclusion criteria: * treatment for hyperthyroidism

Keywords: insulin resistance gastric bypass
comparison of two nasoalveolar molding techniques in complete unilateral cleft lip patient

Conditions: Unilateral Complete Cleft Lip

Summary: two types of presurgical nasoalveolar molding (nam) coexist in craniofacial center in chang gung memorial hospital. the objective of this study is to compare the number of clinical visits, total prices, complications and nasal symmetry between these two nam reconstruction methods.

grayson's nam reconstruction starts with alveolar molding first. the alveolar molding is made by gradual modification of the acrylic plate with periodic acrylic add on and grinding. after the alveolar cleft gap is less than 5 mm (usually at the end of second months), nasal molding was added to the alveolar molding plate. figueroa's nam reconstruction use labial tapes and acrylic relief to the palatal plate to approximate alveolar gap. the device starts with nasal and alveolar molding simultaneously.

Eligibility criteria:
inclusion criteria: * complete unilateral cleft lip infant * signed informed consent exclusion criteria: * incomplete unilateral cleft lip infant * association of other craniofacial anomalies

Keywords: unilateral complete cleft lip, nasoalveolar molding
study comparing sequential therapy of s1+docetaxel followed by s1 to concomitant s1+docetaxel for advanced gastric cancer

Conditions: Gastric Cancer

Summary: stage 1:first line therapy sequential therapy of s1+docetaxel followed by s1 is superior to concomitant s1+docetaxel in the safety and clinical efficiency. stage 2:second line therapy to explore the feasibility of single drug(s1) maintenance treatment for advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * signed informed consent form * performance status-eastern cooperative oncology group (ecog) 0-1 * histologically or cytologically confirmed gastric cancer * advanced or recurrent, metastatic disease * at least have one measurable disease(according to recist, response evaluation criteria in solid tumors ) * life expectancy of at least 3 months * target target lesion has not received radiotherapy or non target lesion radiation at least 4 weeks * haematopoietic and hepatic status: absolute neutrophil count \>1.5x109/l,platelet count \> 100 x 109/l,hemoglobin at least 9 g/dl,bilirubin ≤ 1.5 x upper limit of normal (uln),ast and alt ≤ 2.5 times uln(no liver metastasis), ≤5 times uln(with liver metastasis) * cardiovascular: baseline lvef 50% measured by echocardiography exclusion criteria: * symptomatic brain metastasis * active or uncontrolled infection * unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2; peripheral neuropathy of grade 2 or greater symptomatic brain metastasis * known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, uncontrolled hypertension (≥ 180/110), unstable diabetes mellitus, dyspnea at rest, or chronic therapy with oxygen * history of other malignancy * pregnant or lactating women
iop-lowering efficacy of brinzolamide 1.0% added to travoprost 0.004%/timolol 0.5% fixed combination as adjunctive therapy

Conditions: Glaucoma

Summary: uncontrolled glaucoma patients being treated with a prostaglandin agent alone or in combination with adjunctive drugs in fixed or unfixed combinations, will be switched from their current therapy to travoprost/timolol fixed combination and either azopt or placebo


Eligibility criteria:
inclusion criteria: * glaucoma exclusion criteria: * under 18

Keywords: glaucoma
azithromycin combination therapy for the treatment of severe malaria

Conditions: Falciparum Malaria

Summary: a randomized controlled trial to assess the safety and efficacy of azithromycin combination therapy for use in severe malaria. this pilot trial will be conducted in uncomplicated malaria patients in southeastern bangladesh.


Eligibility criteria:
inclusion criteria: male and female participants with a diagnosis of acute falciparum malaria meeting all criteria listed below may be included in the study: 1. acute symptomatic falciparum malaria infection with a parasite density of 100 to 100,000 asexual parasites/ul as determined on the screening smear with fever (defined as ≥37.5ºc), or reported history of fever within the last 48 hours. 2. age: 8-65 years old 3. males or females. all females over the age of 12 are required to have a negative human chorionic gonadotropin (hcg) pregnancy test (urine). all females of childbearing potential (not surgically sterile, or less than two years menopausal) are required to use an acceptable method of contraception, such as implant, injectable, oral contraceptive(s) with additional barrier contraception, intrauterine device, sexual abstinence, or vasectomized partner, throughout the study 4. written informed consent obtained 5. willing to stay under close medical supervision for the study duration 6. otherwise healthy outpatients exclusion criteria: participants presenting with any of the following will not be included in the study: 1. pregnant women, nursing mothers, or women of childbearing potential who do not use an acceptable method of contraception (as described in inclusion criteria, #3) 2. mixed malaria infection on admission by malaria smear 3. a previous history of intolerance or hypersensitivity to the study drugs artesunate, azithromycin or to drugs with similar chemical structures 4. malaria drug therapy administered in the past 30 days by history 5. history of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness, which in the opinion of the investigator would place them at increased risk. 6. symptoms of severe vomiting (no food or inability to take food during the previous 8 hours). 7. signs or symptoms of severe malaria (as defined by who 2003) 8. unable and/or unlikely to comprehend and/or follow the protocol